One of the most promising applications of targeted therapy is its ability to enhance the response of cancers to currently available cytotoxic drugs. Ovarian cancer provides an important opportunity for this type of intervention. Although ovarian cancer patients have a response rate of 70% to primary treatment with platinum and paclitaxel, more than half of treated patients experience tumor recurrence and ultimately die of this disease (1,2). Paclitaxel is a drug that binds to microtubules, promotes their assembly, and blocks cell division at the G 2 /M phase of the cell cycle (3,4). When used as a single agent to treat ovarian cancer, paclitaxel produces an objective response in fewer than 50% of patients and does not enhance the 70% response rate that has been observed with platinum alone (5-8). Effective strategies to improve the response to paclitaxel treatment could result in improved patient outcomes.
One of the most promising applications of targeted therapy is its ability to enhance the response of cancers to currently available cytotoxic drugs. Ovarian cancer provides an important opportunity for this type of intervention. Although ovarian cancer patients have a response rate of 70% to primary treatment with platinum and paclitaxel, more than half of treated patients experience tumor recurrence and ultimately die of this disease (1, 2) . Paclitaxel is a drug that binds to microtubules, promotes their assembly, and blocks cell division at the G 2 /M phase of the cell cycle (3, 4) . When used as a single agent to treat ovarian cancer, paclitaxel produces an objective response in fewer than 50% of patients and does not enhance the 70% response rate that has been observed with platinum alone (5) (6) (7) (8) . Effective strategies to improve the response to paclitaxel treatment could result in improved patient outcomes.
Given the regulation of cancer cell proliferation and survival by different kinases (9, 10) and the increasing availability of inhibitors of those kinases (11, 12) , we used a library of silencing RNAs (siRNAs) that target all known human protein kinases to identify molecular targets whose decreased expression overcomes paclitaxel resistance and increases paclitaxel activity in ovarian cancer cells. By using siRNAs and small-molecule inhibitors, we validated the findings from the siRNA screen in vitro and in vivo and investigated the underlying mechanisms by which inhibition of Src family members enhances paclitaxel cytotoxicity in ovarian cancer cells.
ARTICLE
The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells
Background
Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity.
Methods
A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. The roles of p27 Kip1 , Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. All statistical tests were two-sided.
Results
Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control siRNA. HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs 0.81 cm
Pan-Kinome siRNA Library Screen
We used a reverse siRNA transfection procedure (ie, cells were added to siRNAs that were applied to 96-well plates) with an siARRAY Protein Kinase siRNA Library v3.0 (SMARTpool, Cat. G-003500; Dharmacon, Lafayette, CO) to identify potential targets that regulate the activity of paclitaxel in SKOv3 cells (Figure 1, A) . Briefly, SKOv3 cells (3 × 10 3 cells per well) were reverse transfected with the use of 12.5 nM DharmaFECT 4 transfection reagent (Dharmacon) in triplicate in 96-well plates that contained 779 distinct kinase siRNAs (each at 15 nM) from the siRNA library, a positive siRNA control (siTOX; Dharmacon) for measuring the efficiency of siRNA delivery, and a RISC-Free siRNA (Dharmacon) or Silencer Negative Control 1 siRNA (Ambion, Austin, TX) as a negative control. Paclitaxel (at 20 nM diluted in PBS) was added to the plates before addition of the cells. The optimal seeding density for SKOv3 cells and the optimal concentration of paclitaxel for SKOv3 were determined in pilot experiments. The plates were incubated at 37°C overnight. Supernatants were replaced with fresh complete medium with or without paclitaxel, and the cells were incubated at 37°C for 48 hours and then assayed for proliferation by use of a crystal violet assay (see below). To determine whether transfection had an effect on gene expression, we included cells transfected with DharmaFECT 4 transfection reagent alone as another negative control (mock-transfected control) in every experiment. Kinases were selected for future study when the difference in growth (assessed by crystal violet staining) between cells incubated with an individual kinase siRNA plus paclitaxel and cells incubated with the negative control siRNA plus paclitaxel attained statistical significance (P < .05 by two-sided Student t test).
Cell Proliferation Assays
A crystal violet cell proliferation assay was used to assess anchoragedependent cell proliferation as described previously (13) . Briefly, HEY (4 × 10 3 ) or SKOv3 (8 × 10 3 ) cells were seeded in triplicate in 96-well cell culture plates and either reverse transfected for 24 hours with a negative control siRNA or a specific siRNA and incubated for an additional 48 hours with or without paclitaxel (3 nM for HEY cells and 6 nM for SKOv3 cells) or treated for 3 days with 0.1% DMSO control, dasatinib (50 nM for HEY and 100 nM for SKOv3), paclitaxel (3 nM for HEY and 6 nM for SKOv3), or both agents combined. The cells were washed with PBS, fixed in 1% glutaraldehyde, and stained with 0.5% crystal violet (Sigma Chemical Co) dissolved in methanol. The dye that stained the cells on the plates was eluted with Sorenson buffer (0.9% sodium citrate, 0.02 N HCl, and 45% ethanol) and directly measured with the use of a Vmax microplate reader (Molecular Devices, Sunnyvale, CA) at a wavelength of 560 nm. Cell number was expressed as the optical density at 560 nm.
Validation of Src Family and Abl Kinases
The ability of individual siRNAs to knock down Src, Fyn, and Abl1 kinases and to enhance paclitaxel sensitivity was confirmed with at 
B)
Validation of the effect of Src siRNA (siR) on paclitaxel-mediated growth inhibition in SKOv3 cells. Cells on 96-well plates were reverse transfected with a control siRNA or an Src siRNA (Ambion) for 24 hours and treated with or without 6 nM paclitaxel (Pac) for an additional 48 hours. A crystal violet cell proliferation assay was used to measure the number of viable cells (expressed as the optical density at 560 nm). *P = .031 vs control siR plus Pac. C) Validation of the effect of Fyn siRNA on paclitaxel-mediated growth inhibition in SKOv3 cells. The reverse transfection method described in (B) was used with a Fyn siRNA from Ambion. *P = .028 vs control siR plus Pac. D) Validation of the effect of Abl1 siRNA (Ambion) on paclitaxel-mediated growth inhibition in SKOv3 cells. A conventional transfection method was used with an Abl1 siRNA from Ambion. *P = .037 vs control siR plus Pac group. Data shown in panels (B-D) are mean values from three independent experiments. E) Clonogenic assay to assess the effects of control siRNA or Src siRNA on colony formation by paclitaxel-sensitive ovarian cancer HEY cells treated for 14 days with diluent (control) or 3 nM paclitaxel (Pac). §P = .031 vs control siR plus Pac. *P = .015 vs control siR plus Pac. **P = .005 vs control siR plus Pac. F) Clonogenic assay to assess the effects of control siRNA or Src siRNA on colony formation by paclitaxel-resistant ovarian cancer OVCA420 cells treated for 14 days with diluent (control) or paclitaxel (Pac). *P = .021 vs control siR plus Pac. G) Clonogenic assay to assess the effects of control siRNA or Src siRNA on colony formation by HEY ovarian cancer cells treated for 14 days with diluent (control) or 15 µM cisplatin (CDDP). *P = .03 vs control siR plus CDDP group. Data in panels (E-G) are the mean number of colonies (counted manually) from assays performed in triplicate. All P values were calculated using the two-sided Student t test. Error bars correspond to 95% confidence intervals.
least three specific siRNAs for each kinase obtained from Ambion using the Silencer Negative Control 1 siRNA as a negative control according to the method previously reported (13) . To test each siRNA, we conducted both conventional transient transfection assays (ie, cells seeded 1 day before transfection) as previously described (14) and reverse transfection assays (ie, cells seeded on top of the transfection mixture) as described in the previous section. The following pre-validated proprietary siRNAs (Ambion) were used for validation: SRC gene ID = 6714, siRNA ID = s13414; FYN gene ID = 2534, siRNA ID = s5435; ABL1 gene ID = 25, siRNA ID = s864. The final concentrations of siRNAs and DharmaFECT 4 for both types of transfection were 15 and 12.5 nM, respectively. SKOv3 cells (8 × 10 3 cells per well) or HEY cells (4 × 10 3 cells per well) were seeded in triplicate in 96-well plates. Paclitaxel (3 nM for HEY cells and 6 nM for SKOv3 cells) was also added to the wells containing the siRNA-DF 4 complexes. The transfected cells were typically incubated for 16 hours before the supernatants were removed and replaced with fresh complete medium containing paclitaxel. Cells were cultured for an additional 48 hours and stained with crystal violet in methanol to assess proliferation.
Clonogenic Assay
A colony formation (ie, clonogenic) assay was performed as described previously (14) . Briefly, SKOv3 or HEY cells were seeded at 1000 and 500 cells per well in triplicate and treated for 14 days with either DMSO as a control or with dasatinib (10 nM for SKOv3 cells and 5 nM for HEY cells) and/or paclitaxel (0.6 nM for SKOv3 and 0.3 nM for HEY). Cells were then fixed in 1% glutaraldehyde and stained with 0.5% crystal violet (Sigma) in methanol. Colonies with more than 30 cells were counted.
Preparation of Total RNA
Total RNA was extracted with the use of TRIZOL reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. RNA purity was assessed by measuring absorption at 260 nm (A260) and at 280 nm (A280) (samples that had A260/A280 ratio of 1.9-2.1 were considered acceptable) and by ethidium bromide staining of 18S and 28S RNA on gels after electrophoresis. RNA concentrations were determined from absorbance at 260 nm (A260).
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) Analysis of mRNA Expression qRT-PCR was performed with the use of a Prism 7900HT Sequence Detection System (Applied Biosystems Incorporated, Foster City, CA) and SYBR Green Universal PCR Master Mix (Bio-Rad Laboratories, Hercules, CA), as described previously (15) . Total RNA isolated from SKOv3 cells transfected with individual siRNAs was reverse transcribed into cDNA with the use of a cDNA kit (Invitrogen, Carlsbad, CA), and the cDNA was subjected to qRT-PCR to assess mRNA levels of Src, Fyn, Abl, and Bcl-2. Oligonucleotide sequences of the primer sets used were as follows: human SRC (forward 5′-CGACTTTGGGCTGGCTC GGCTCATT-3′, reverse 5′-ACCTGGTCCAGCACCTCGCG GTTCA-3′); human FYN (forward 5′-CTCAGCACTACCCC AGCTTC-3′, reverse 5′-CATCTTCTGTCCGTGCTTCA-3′);
human ABL1 (forward 5′-AACACCCTAACCTGGTGCAG-3′, reverse 5′-CAAGTGGTTCTCCCCTACCA-3′); human BCL2 (forward 5′-GGGTACGATAACCGGGAGAT-3′, reverse 5′-CT GAAGAGCTCCTCCACCAC-3′); and human GAPDH (forward 5′-CGTCTTCACCACCATGGAGA-3′, reverse 5′-CGGCCAT CACGCCACAGTTT-3′). Primers were synthesized by SigmaGenosys (Houston, TX). PCR was performed in a total volume of 30 µL, which included 15 µL of 2× universal PCR master mix, 3 µL of 10× SYBR Green, 20 µM of each forward and reverse primer, and 50 ng of each cDNA sample. Amplifications were carried out in triplicate in 96-well microtiter plates (Applied Biosystems Incorporated). Thermal cycling conditions were as follows: 95°C for 5 minutes, followed by 40 cycles of 95°C for 10 seconds, and 59°C for 40 seconds. A melting curve analysis was used for all primer sets to exclude nonspecific amplification and consisted of 95°C for 15 seconds, 59°C for 15 seconds, followed by increasing the temperature by 1°C every 2 seconds until 95°C, and then 95°C for 15 seconds. HEY or SKOv3 cells (2 × 10 6 ) were treated with DMSO, dasatinib, paclitaxel, or a combination of the drugs and then lysed in RIPA buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, and 1 mM sodium orthovanadate). The lysates were subjected to immunoprecipitation as described previously (13) . Briefly, aliquots of the whole-cell lysates (~500 µg) were incubated overnight at 4°C with the following mouse antibodies (~1 µg of each): antiCdk1 (Cat. PC-25; EMD Chemicals, Gibbstown, NJ) or anti-Cdk2 (Cat. sc-163), anti-Cdk4 (Cat. sc-601), anti-Cdk6 (Cat. sc-177), or anti-p27 Kip1 (Cat. sc-528; all from Santa Cruz Biotech, Santa Cruz, CA). Mouse serum was used a negative immunoprecipitation control. Antibody-antigen complexes were collected with the use of protein A-agarose beads (GE Healthcare, Piscataway, NJ) and washed three times washing with RIPA buffer. The beads were boiled in sodium dodecyl sulfate (SDS) loading buffer (20 mM Tris-HCl [pH 6.8], 0.3% SDS, 3.3% glycerol, 0.03% bromophenol blue), and the supernatants were resolved by electrophoresis on a 12% SDS-polyacrylamide gel, transferred to a membrane, and immunoblotted as described previously (13) with rabbit antibodies against Cdk1 (1:500 dilution, Cat. sc-54; Santa Cruz Biotech), Cdk2 (1:1000, Cat. # MS-617; Neomarkers, Fremont, CA), Cdk4 (1:1000, Cat. sc-23896; Santa Cruz Biotech), Cdk6 (1:500, Cat. MS-398; Neomarkers), p21 Cip1 (1:300, Cat. sc-6246; Santa Cruz Biotech), or p27 Kip1 (1:1500, Cat. 610241; BD Pharmingen, San Diego, CA). The membrane was incubated with horseradish peroxidase-conjugated secondary antibody (1:2000 dilution; GE Healthcare), and bound antibody was visualized with the use of a SuperSignal West Dura chemiluminescent kit (Thermo Fisher, Rockford, IL). Other antibodies used in immunoblotting were against active caspase-3 (1:1000 dilution, mouse monoclonal antibody; Millipore, Temecula, CA); GAPDH (1:3000 dilution, mouse monoclonal antibody; Millipore); phospho-T160 Cdk1 (1:500 dilution, rabbit polyclonal antibody; Cell Signaling, Boston, MA); phospho-Y412 Abl (1:300 dilution, rabbit polyclonal antibody; ECN Biosciences, Versailles, KY); phospho-T187/phospho-T157/ phospho-S10 p27 Kip1 (1:500 dilution, rabbit polyclonal antibody; Abgent, San Diego, CA), and phospho-tyrosine (clone 4G10) (1:2500 dilution, mouse monoclonal antibody; Millipore).
Immunoprecipitation and Immunoblot Analysis

Sub-G 1 Fraction and Cell Cycle Distribution Determined by Flow Cytometry
The percentage of cells in the sub-G 1 phase of the cell cycle (ie, apoptotic cells) was determined based on relative DNA content as determined with the use of flow cytometry as described previously (13) . Briefly, 5 × 10 5 HEY cells were treated with dasatinib (50 nM), paclitaxel (3 nM), the combination, or DMSO (control) for 24 hours and were then detached by incubating with 0.05% trypsin-EDTA, washed with PBS, and fixed overnight in 70% ethanol. Fixed cells were then centrifuged, washed, resuspended in PBS containing RNase A and propidium iodide (50 µg/mL each) and incubated for 20 minutes at 37°C with gentle shaking. Stained cells were filtered through nylon mesh (41-µm pore size) and analyzed on a Coulter flow cytometer XL-MCL (Coulter Corporation, Miami, FL). The percentages of sub-G 1 population and cell cycle distribution were determined using the MULTICYCLE software program (Phoenix Flow Systems, San Diego, CA).
Ovarian Cancer HEY Xenografts in Nude Mice
HEY cells (10 6 ) in 0.1 mL PBS were injected subcutaneously into each of two sites on the opposite flanks of 4-week-old BALB/c athymic Nu/Nu mice (obtained from the in-house animal facility at the Department of Experimental Radiation Oncology, M. D. Anderson Cancer Center). Experiments with Nu/Nu mice were reviewed and approved by the Institutional Animal Care and Use Committee (M. D. Anderson Cancer Center). All mice were maintained under specific pathogen-free conditions and given sterile food and water. Once the tumors became palpable (at day 7 after injection), the mice were randomly assigned to the following treatment groups (n = 6 mice per group): 1) intraperitoneal injection five times per week with dasatinib (10 mg/kg body weight), 2) intraperitoneal injection once per week with paclitaxel (10 mg/kg body weight), 3) and 4) intraperitoneal injection five times per week with dasatinib (10 mg/kg body weight) and once per week with paclitaxel (10 mg/kg body weight) (two groups), or 5) intraperitoneal injection five times per week with DMSO (50 µL). All mice were treated for 3 weeks. Tumor sizes and body weights were measured twice per week by one author (WM), who was blinded to the treatment group. Treatment was stopped at day 31 after tumor cell injection in all groups, and mice in all but one group were killed by CO 2 asphyxiation. Mice in one group that received paclitaxel and dasatinib were monitored without further treatment for an additional 9 days and then killed by CO 2 asphyxiation. All tumors were collected immediately after death, weighed, and used for RNA and protein isolation, fixed in formalin and embedded in paraffin, or frozen in liquid nitrogen. The tumor volumes (in cm 3 ) were calculated using the formula = a × b 2 × 0.5236, where a is the longest diameter, b is the shortest diameter, and 0.5236 is a constant to calculate the volume of an ellipsoid, as described previously (16) . Each mouse formed two tumors (tumor take rate = 100%). Power analysis was conducted in the G-Power software using analysis of variance with the Scheffe post hoc test (one-tailed) (17) and showed that a sample size of six in each group as described above produced 84.2% power to detect 30% reduction in tumor size or tumor weight at a statistical significance level of 5%. Average tumor volume per mouse was the mean of the tumors formed at the two injection sites. All tumors (average 16-20 tumors per treatment group) from two independent experiments were included for final calculation of tumor volume and weight. Experiments with nude mice were repeated twice.
Apoptosis Rescue Experiment With Caspase Inhibitor
HEY cells (1 × 10 6 ) were pretreated for 2 hours with 20 µM of either a caspase-3 inhibitor (Z-DEVD-FMK), a pan-caspase inhibitor (Z-VAD-FMK), or a negative control (Z-FA-FMK), followed by treatment for 24 hours with dasatinib (50 nM) plus paclitaxel (3 nM) (D + P). The cells were then fixed in 70% ethanol, stained with propidium iodide, and subjected to sub-G 1 population analysis by flow cytometry. The sub-G 1 cell fraction is considered the apoptotic cell population and expressed as percentage of the total cell population.
Terminal Deoxynucleotidyl Transferase (TDT)-mediated dUTP Nick-end Labeling (TUNEL) Assay HEY xenograft tumor sections (3-µm thick) were deparaffinized and digested with proteinase K (20 µg/mL; Roche). Then sections were incubated with TDT (0.3 U/µL) and with biotinylated dUTP (0.2 mM; Roche) in 1× TDT buffer (Invitrogen, Carlsbad, CA) for 1 hour at 37°C. The sections were incubated in 10% normal horse serum to block nonspecific binding, followed by incubation for 1 hour at room temperature with avidin-biotin complex (1:100 dilution) from a Vectastain Elite ABC Kit (Vector Lab, Burlingame, CA). The sections were stained with 0.125% amino-ethyl carbazole (AEC) or AEC buffer (Sigma), counterstained with Mayer's hematoxylin (DakoCytomation, Carpinteria, CA), and mounted under coverslips in Aqua-mount medium (Thermo Fisher). Sections were examined by confocal microscopy as described above, and digital images at ×100 magnification were obtained using FluoView 1000 software (Olympus Inc, Melville, NY). TUNEL-positive cells were counted in five randomly chosen fields for each tumor section and presented as a percentage of the total number of cells.
Double Immunofluorescence Staining for Active
Caspase-3 and Phospho-histone H3 HEY cells were seeded on cover slips, incubated overnight, and then treated with dasatinib (50 nM), paclitaxel (3 nM), the combination, or diluent (DMSO) for 24 hours. The cells were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, incubated with 2% bovine serum albumin for 30 minutes at room temperature to block nonspecific protein binding, and incubated for 2 hours at room temperature with a mouse monoclonal antibody against phospho-S10-histone H3, a marker for cells in M phase of the cell cycle (1:150 dilution; Cell Signaling) or a rabbit polyclonal antibody against active caspase-3, a marker for cells in apoptosis (1:200 dilution; Millipore). The cover slips were then incubated with Alexa fluor 488-conjugated F(ab′)2 fragment of goat anti-mouse IgG (H + L) and Alexa fluor 594-conjugated F(ab′)2 fragment of goat anti-rabbit IgG (H + L) (both at 1:500 dilution; Invitrogen, Eugene, OR). The cover slips were mounted in the VECTASHIELD HardSet Mounting Medium with DAPI (Vector Lab) on standard microscope slides and examined with the use of a FluoView 1000 confocal microscope (Olympus Inc). Digital images at high-power magnification (×600) were obtained with the use of FluoView 1000 software (Olympus Inc).
Bromodeoxyuridine (BrdU) Labeling
BrdU labeling was performed with the use of a flow cytometrybased EZ-BrdU assay kit (Phoenix Flow Systems) to determine the effects of dasatinib and p27
Kip1 on S phase of the cell cycle. Briefly, HEY cells (0.5 × 10 6 ) were transiently transfected either control siRNA or a p27
Kip1 siRNA (Ambion) and incubated for 48 hours. The cells were further incubated in the presence of dasatinib (50 nM) or DMSO for 18 hours, then BrdU solution (5 µg/mL) was added, and the cells were incubated for another 6 hours. The cells were fixed in ice-cold 70% ethanol (vol/vol) and stored overnight in a freezer. After denaturation and neutralization of the cellular DNA, the cells were stained with a fluorescein-labeled anti-BrdU antibody for 60 minutes, and then incubated with a propidium iodide-RNase A solution for 30 minutes. The cells were analyzed by flow cytometry within 3 hours of the staining. Clones of HEY cells with stable expression of Bcl-2 were established as reported previously (14) .
Infection With p27
Kip1 Adenovirus HEY cells (2 × 10 5 ) were seeded in 60-mm cell culture dishes in triplicate with 10% Tet-free FBS (Clontech Labs, Mountain View, CA) in the presence or absence of doxycycline (1 µg/mL; Clontech Labs), infected with a 1:1 ratio of an adeno-X Tet-Off regulatory virus (Clontech Labs) and the Tet-off p27
Kip1 adenovirus (19) at different multiplicities of infection (MOI) or at an MOI of 10 for 8 hours, and then treated with paclitaxel (3 nM) for an additional 24 hours. Cells were then harvested for immunoblotting and flow cytometry.
Apoptosis PCR Array Analysis
We used an apoptosis PCR array (Cat. PAHS-012; SABiosciences, Frederick, MD), according to the manufacturer's protocol, to analyze the expression of 84 key genes involved in apoptosis. Briefly, HEY cells were treated with dasatinib (50 nM), paclitaxel (3 nM), the combination, or DMSO for 24 hours. Total RNA was extracted and reverse transcribed into cDNA with the use of an RT 2 First Strand Kit (SABiosciences). The templates were combined with an RT 2 SYBR Green qPCR Master Mix (SABiosciences), and then equal aliquots of this mixture (25 µL) were added to each well of the same PCR Array plate that contained the pre-dispensed gene-specific primer sets. The qRT-PCR was performed with the use of a Prism 7900HT Sequence Detection System (Applied Biosystems Incorporated) as described above. Fold change in gene expression for all the genes was calculated using the comparative cycle threshold C T (DDC T ) method (15) .
Cell Synchronization
HEY cells (5 × 10 6 ) were transiently transfected with either control siRNA or a p27
Kip1 siRNA (Ambion) as described above and incubated for 30 hours. The cells were treated with 2 mM thymidine for 16 hours to block cell cycle progression at the G 1 -S boundary of the cell cycle. Cell synchronization at the G 1 -S boundary was confirmed by flow cytometry. The cells were washed three times in PBS followed by incubation in thymidine-free complete RPMI-1640 medium containing 10% FBS and paclitaxel (3 nM). The cells were harvested at different times after this release from the thymidine block and subjected to immunoblot analysis with the following antibodies: p-HH3 (1:1000 dilution; Cell Signaling), Cdk1 (1:500 dilution; Santa Cruz), active caspase-3 (1:1000 dilution; Millipore), p27Kip1 (1:1500 dilution; BD Pharmingen), and GAPDH (1:3000 dilution; Millipore).
Subcellular Fractionation
HEY cells (2 × 10 6 ) were treated for 24 hours with dasatinib (50 nM) or DMSO (control) and then fractionated with the use of a Nuclear and Cytoplasmic Extraction Kit (Promega, Madison, WI) according to the manufacturer's instructions. Equal amounts of protein from the cytoplasmic and nuclear extracts (10 µg) were subjected to immunoblot analysis with antibodies against p-Y416 Src (1:500 dilution; Cell Signaling), total Src (1:1000 dilution; Cell Signaling), p27Kip1 (1:1500 dilution; BD Pharmingen), Cdk2 (1:1000 dilution; Neomarkers), p-S473 AKT (1:500 dilution; Cell Signaling), PARP (1:1000 dilution; BD Pharmingen), and a-tubulin (1:1000 dilution; Sigma).
Statistical Analysis
All experiments were repeated at least twice on different occasions. All data are presented as mean values with 95% confidence intervals (CIs). A two-sided Student t test was used to compare the differences between two groups. Analysis of variance was used to compare the differences among multiple groups. Statistical significance was defined as a P value less than .05. All statistical tests and corresponding P values were two-sided.
Results
Kinome siRNA Screen to Identify Kinases That Modulate the Sensitivity of Ovarian Cancer Cells to Paclitaxel
To identify kinases that regulate the activity of paclitaxel, we reverse transfected human ovarian cancer SKOv3 cells with a library of siRNAs that target 779 different kinases, incubated the transfectants in the presence and absence of paclitaxel, and assayed for specific siRNAs that were capable of statistically significantly enhancing paclitaxel cytotoxicity compared with a negative control siRNA (Figure 1, A) . Overall, siRNA knockdown of 72 kinase targets statistically significantly enhanced paclitaxel cytotoxicity (Supplementary Table 1 , available online). Notably, siRNA knockdown of four members of the Src family of kinases-FYN oncogene related to SRC, FGR, and YES (FYN; P = .014); hematopoietic cell kinase (HCK; P = .014); Fyn binding protein (FYB; P = .025); and Fyn-related kinase (FRK; P = .03)-and of two Abl kinases-ABL1 (P = .014) and ABL2 (P = .002)-statistically significantly inhibited SKOv3 cell proliferation in the presence of paclitaxel to a greater extent compared with a control siRNA (Supplementary Figure 1 , available online). The siRNA knockdown of other Src family kinases, including Src (P = .06), Yes (P = .06), Blk (P = .05), and Fgr (P = .07), also increased the sensitivity of SKOv3 cells to paclitaxel, but the results did not reach statistical significance during this initial screen. However, in subsequent validation experiments, knockdown of Src kinase with an siRNA that had a different sequence from that included in the library statistically significantly (P = .031) enhanced paclitaxel sensitivity of SKOv3 cells compared with a control siRNA (Figure 1 . qRT-PCR analysis revealed that the Src, Fyn, or Abl1 siRNAs reduced the levels of the respective mRNA by at least 80% compared with negative control siRNA in SKOv3 cells, both in the presence and absence of paclitaxel (data not shown). These data demonstrate that Src family and Abl kinases modulate paclitaxel sensitivity and that inhibition of these kinases with siRNAs makes ovarian cancer cells more sensitive to paclitaxel.
Effects of Dasatinib on Phosphorylation of Src and Abl Kinases and on Paclitaxel Activity in Cell Cultures and Xenografts
Dasatinib is a small-molecule inhibitor of Src family and Abl kinases (20, 21) that has been approved by the US Food and Drug Administration (FDA) for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant to imatinib (22) . Given our finding that siRNA-mediated knockdown of Src family and Abl kinases enhanced the sensitivity of ovarian cancer cells to paclitaxel, we examined whether dasatinib would similarly enhance the sensitivity of ovarian cancer cells to paclitaxel. The ability of dasatinib to enhance paclitaxel activity was further tested in a HEY xenograft model in Nu/Nu mice. Mice with established HEY ovarian tumors were treated for 3 weeks by intraperitoneal injection with DMSO (control), dasatinib alone, paclitaxel alone, or a combination of dasatinib plus paclitaxel, and tumor growth was measured. Treatment of the mice with dasatinib plus paclitaxel produced greater inhibition of tumor volume compared with all other treatments (average tumor volume per mouse on day 31, dasatinib + paclitaxel vs diluent: 0. 28 (Figure 2 , G) Similarly, treatment of the mice with dasatinib plus paclitaxel produced greater inhibition of tumor growth as measured by tumor weight compared with all other treatments (average tumor weight per mouse, dasatinib + paclitaxel = 0.38 g; diluent control = 1.28 g; paclitaxel alone = 0.85 g; dasatinib alone = 0.6 g) (Figure 2, H) . In addition, the antitumor activity of the combination treatment in vivo was sustained because the mice in the combination treatment group that received no further drug treatment after day 31 had no obvious tumor regrowth for at least 9 days (Figure 2, G) . Effects of dasatinib on phosphorylation of Src and Abl kinases and paclitaxel activity in cell culture and in xenografts. A) Dose-dependent inhibition of Src phosphorylation at Tyr416 by dasatinib (Das). Total protein lysates from HEY cells treated with dasatinib at the indicated concentrations for 24 hours were analyzed for Src phosphorylation at Tyr416 (p-Y416 Src) and total Src by immunoblotting. B) Dose-dependent inhibition of Abl1 phosphorylation at Tyr412 by dasatinib. HEY cells were treated as described in (A). Actinin served as a loading control. The p-Y412 Abl expression was normalized to actinin levels and expressed as relative fold change. The p-Y412 Abl expression in the DMSO-treated tumors (0 nM) was arbitrarily set to 1. C) Cell viability assay of effect of dasatinib on paclitaxel-induced cytotoxicity in HEY cells. Cells in 96-well plates were treated with 0.1% DMSO (CTRL), dasatinib (50 nM), paclitaxel (3 nM), or both agents combined (Das + Pac) for 3 days. A crystal violet cell proliferation assay was used to measure the number of viable cells (expressed as the optical density at 560 nm). *P = .019; **P = .025 (two-sided Student t test). Data shown in panels (C) and (D) are mean values from three independent experiments. D) Cell viability assay of effect dasatinib on paclitaxel-induced cytotoxicity in SKOv3. Ovarian cancer cells were treated with 0.1% DMSO (CTRL), dasatinib (100 nM), paclitaxel (6 nM), or both agents combined (Das + Pac) for 3 days and assayed as described in (C). *P = .034; **P = .029 (two-sided Student t test). E) Clonogenic assay of the effect of dasatinib on paclitaxel-induced cytotoxicity in HEY cells. Cells (500 per well in six-well plates) were treated with 0.1% DMSO (CTRL), dasatinib (5 nM), paclitaxel (0.3 nM), or both agents combined (Das + Pac) for 7 days. Colonies were visualized by staining with crystal violet and manually counted. *P = .003; **P < .001 (two-sided Student t test). F) Clonogenic assay of the effect of dasatinib on paclitaxel-induced cytotoxicity in SKOv3 cells. SKOv3 cells (1000 per well in six-well plates) were treated with 0.1% DMSO (CTRL), dasatinib (10 nM), paclitaxel (0.6 nM), or both agents combined (Das + Pac) for 7 days. Colonies were visualized by staining with crystal violet and manually counted. *P = .005; **P < .001 (two-sided Student t test). G) Effects of dasatinib, paclitaxel, and the combination on subcutaneous HEY xenograft tumor growth in Nu/Nu mice as measured by tumor volume. Mice bearing HEY xenograft tumors (six mice per group) were treated for 3 weeks by intraperitoneal injection (IP) with dasatinib (10 mg/kg body weight, five times per week), paclitaxel (10 mg/kg body weight, once per week), dasatinib (10 mg/kg body weight, five times per week) plus paclitaxel (10 mg/kg body weight, once per week), or diluent control DMSO (C). All treatment was stopped at day 31 after tumor cell injection in all groups, and all mice except those in one of the combination treatment groups were killed. Mice in this combination treatment group were monitored without any treatment for additional 9 days (defined as EXT W/O treatment) and then were killed. Green and red arrows indicate the start and end of treatment, respectively. Data are mean values with 95% confidence intervals from two independent experiments. The average tumor volume per mouse was mean of two tumors. All tumors (average 16-20 tumors per treatment group) from two independent experiments were included for the final calculation of tumor volume. *P = .014 vs combination treatment group. **P = .035 vs combination treatment group (two-sided analysis of variance). H) Effect of dasatinib, paclitaxel, and the combination on subcutaneous HEY xenograft tumor growth as measured by tumor weight on day 31 after tumor cell injection. All tumors (average 16-20 tumors per treatment group) from two independent experiments were included for the final calculation of tumor weight. *P = .025 vs combination treatment group. **P = .004 vs combination treatment group (two-sided Student t test). Error bars correspond to 95% confidence intervals.
These data clearly demonstrate that dasatinib, a small-molecule inhibitor of Src family and Abl kinases, enhances the sensitivity of human ovarian cancer cells to paclitaxel in cell culture and in xenografts.
Mechanism of Dasatinib Enhancement of Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells and Xenografts
We next explored the mechanism by which dasatinib enhanced the cytotoxic activity of paclitaxel in ovarian cancer cells. In a previous study (14) , we found that dasatinib causes ovarian cancer cells to arrest at the G 1 phase of the cell cycle and induces autophagic cell death [also called type II programmed cell death, which is characterized by extensive autophagic degradation of Golgi apparatus, polyribosomes, and endoplasmatic reticulum before nuclear destruction (23)]. Therefore, we first examined the effect of treating SKOv3 or HEY ovarian cancer cells with dasatinib, paclitaxel, or the combination on the fraction of cells undergoing autophagy. Surprisingly, we observed no increase in the fraction of autophagic cells (determined by acridine orange staining and immunoblotting for the autophagic marker microtubule-associated protein light chain 3) for SKOv3 or HEY cells treated with dasatinib plus paclitaxel vs either drug alone (data not shown). Instead, compared with treatment with either drug alone, combined treatment with dasatinib and paclitaxel produced an increase in the fraction of multinucleated cells (Supplementary Figure 3, available online) , which is typical for cells undergoing apoptosis and/or mitotic catastrophe (24) . For example, flow cytometric analysis revealed that treatment of HEY cells with dasatinib plus paclitaxel produced a greater percentage of apoptotic cells in the sub-G 1 fraction compared with dasatinib or paclitaxel alone (sub-G 1 fraction, dasatinib + paclitaxel vs dasatinib: 35.2% vs 2.2%, difference = 33%, 95% CI = 29% to 37%, P < .001; dasatinib + paclitaxel vs paclitaxel: 35.2% vs 11.5%, difference = 23.7%, 95% CI = 21.0% to 27.3%, P = .018) (Figure 3, A) . In agreement with these results, immunoblot analysis of the treated HEY cells revealed that the combination treatment induced more active caspase-3 (a marker for cells undergoing apoptosis) compared with dasatinib or paclitaxel alone (Figure 3, B) . We next examined the effects of a caspase-3-specific inhibitor and a pan-caspase inhibitor on apoptosis in HEY cells treated with dasatinib plus paclitaxel. Both the caspase-3-specific (Z-DEVD-FMK) and the pan-caspase (Z-VAD-FMK) inhibitors, but not the negative inhibitor control (Z-FA-FMK), statistically significantly blocked combination treatment-induced apoptosis, further supporting the notion that caspase-3 mediated apoptosis induced by treatment of HEY cells with the combination (sub-G 1 fraction, negative control inhibitor vs caspase-3 inhibitor: 42.5% vs 23.1%, difference = 19.4%, 95% CI = 16.9% to 21.9%, P = .029) (Figure 3, C) . The sub-G 1 fraction in cells treated with dasatinib plus paclitaxel and the pan-caspase inhibitor was 21.1% compared with 42.5% in negative control inhibitor-treated cells (difference = 21.4%, 95% CI = 19.8% to 23%, P = .02) (Figure 3, C) .
To examine whether dasatinib enhanced paclitaxel-induced apoptosis in vivo, mice bearing xenograft tumors were treated with DMSO, dasatinib alone, paclitaxel alone, or the combination of drugs, and the tumors were subsequently stained using TUNEL to detect apoptotic cells. Xenograft tumors from mice treated with dasatinib plus paclitaxel had more apoptotic (ie, TUNEL-positive) cells compared with tumors from mice treated with either agent alone (percentage of TUNEL-positive cells in five randomly selected fields, dasatinib + paclitaxel vs dasatinib: 43.2% vs 12.4%, difference = 30.8%, 95% CI = 27.1% to 34.5%, P < .001; dasatinib + paclitaxel vs paclitaxel: 43.2% vs 25.6%, difference = 17.6%, 95% CI = 14.8% to 20.4%, P = .033) (Figure 3, D and E) . Immunoblot analysis of tumor lysates revealed that HEY ovarian cancer xenografts from mice treated with dasatinib plus paclitaxel expressed more activated caspase-3 compared with xenografts from mice treated with either agent alone (Figure 3, F) . After normalizing to GAPDH levels, the relative level of active caspase-3 was 3.1 in mice treated with dasatinib plus paclitaxel, 1.2 in mice treated with dasatinib alone, and 1.7 in mice treated with paclitaxel alone (Figure 3, F) . Furthermore, increased caspase-3 activity persisted at least 9 days after the last drug treatment with dasatinib and paclitaxel (Figure 3, F) , consistent with the observed persistent tumor growth inhibition in these mice ( Figure 2 , G and H). Treatment with a combination of dasatinib and paclitaxel also decreased tyrosine phosphorylation of Src at residue 416 in tumor lysates (Figure 3, F) , consistent with our previous observations in cell culture (Figure 2, A) . Taken together, these data indicate that induction of apoptosis is a major mechanism by which dasatinib enhances paclitaxel activity in cell cultures and xenografts.
Effect of Dasatinib and Paclitaxel on Mitotic Catastrophe
As described above, combined treatment of ovarian cancer cells with dasatinib and paclitaxel produced an increase in the fraction of multinucleated cancer cells (Supplementary Figure 3 , available online), which might also be caused by mitotic catastrophe, a special form of apoptosis that occurs during mitosis (24) . Mitotic catastrophe is characterized by chromosomal condensation and caspase activation in addition to these morphological alterations (24) . To examine whether dasatinib or paclitaxel induce mitotic catastrophe, we subjected HEY cells treated with dasatinib, paclitaxel, or both agents combined to triple immunofluorescence staining with an antibody against phosphorylated histone H3 (a marker of M phase), an antibody against active caspase-3 (a marker of apoptosis), and DAPI (a fluorescent DNA stain to examine nuclear morphology). Multinucleated cancer cells (detected by DAPI staining) with immunohistochemical expression of both phospho-histone H3 and active caspase-3 were considered to be undergoing mitotic catastrophe, as shown in Figure 3 , G for cells treated with dasatinib plus paclitaxel. We quantified cells undergoing mitotic catastrophe among 500 DAPIstained cells in each treatment group: 12.5% of cells treated with the combination had undergone mitotic catastrophe, whereas 4.5% of cells treated with paclitaxel alone and no cells treated with dasatinib alone or control exhibited signs of mitotic catastrophe (Figure 3, H) . Immunohistochemical analysis revealed that xenograft tumor sections from mice treated with dasatinib plus paclitaxel had more phospho-histone H3-positive cells than did xenografts from mice treated with either agent alone or control mice (data not shown). Therefore, it appears that combined treatment with dasatinib and paclitaxel causes a fraction of cells to undergo mitotic catastrophe. 3 nM) , the combination, or dimethyl sulfoxide (control), then fixed, stained with propidium iodide, and subjected to cell cycle analysis by flow cytometry. The sub-G 1 cell fraction was considered the apoptotic cell population and expressed as a percentage of the whole-cell population. *P = .018; **P < .001. Data shown are mean values from four independent experiments. B) Immunoblot analysis of caspase-3 activation. Total protein prepared from HEY cells treated as described in (A) was subjected to immunoblot analysis with antibodies for activated caspase-3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; a control for equal protein loading). C) Effects of caspase inhibitors on combination treatment-induced apoptosis. HEY cells were pretreated for 2 hours with 20 µM of either caspase-3 inhibitor (Z-DEVD-FMK; casp 3 inh), a pan-caspase inhibitor (Z-VAD-FMK; pan casp inh), or negative control (Z-FA-FMK; neg inh), followed by treatment for 24 hours with dasatinib (50 nM) plus paclitaxel (3 nM) (D + P). The cells were then fixed in 70% ethanol, stained with propidium iodide, and subjected to cell cycle analysis by flow cytometry. The sub-G 1 cell population is considered the apoptotic cell population and expressed as a percentage of the whole-cell population. Data shown were pooled from three independent experiments. *P = .029, **P = .02. D) Terminal deoxynucleotidyl transferase-mediated dUTP Nick-end Labeling (TUNEL) assay of apoptosis in HEY xenograft tumors. Mice bearing HEY xenograft tumors were treated as described in Figure 2 , G, and tumors were analyzed by the TUNEL method. Apoptotic cells stained in dark brown (red arrows). Scale bars, 25 µm. E) Enumeration of TUNEL-positive cells in tumor sections described in (D). TUNEL-positive cells were counted in five randomly chosen fields at ×100 magnification for each tumor section and presented as a percentage of the total number of cells. *P = .033, **P < .001. F) Immunoblot analysis of apoptosis and Src phosphorylation in xenograft tumor lysates. Lysates of xenograft tumors from mice treated as described in (D) were prepared and subjected to immunoblotting with antibodies against active caspase-3 and Y416-phosphorylated Src. Active caspase-3 expression in the middle panel was digitized with the UN-SCN-IT Gel software (Silk Scientific, Inc Orem, UT), normalized to GADPH levels, and expressed as relative fold change compared with levels in tumors from DMSO-treated mice. Active caspase-3 level in the DMSO-treated tumors (C) was set to 1. Das = dasatinib-treated mice; Pac = paclitaxel-treated mice; D + P = Das + Pac-treated mice; D + P* = Das + Pac-treated mice with nine additional days of observation without treatment. G) Effect of dasatinib and paclitaxel on mitotic catastrophe in HEY cells. HEY cells grown on slides were treated for 24 hours with dasatinib (50 nM) plus paclitaxel (3 nM), then incubated with antibodies against the M phase marker phosphorylated histone H3 (p-HH3; green) and the apoptosis marker active caspase-3 (red), followed by staining of DNA with DAPI (blue). Cells undergoing mitotic catastrophe were identified by colocalization of p-HH3 and active caspase-3 (cyan arrows). Scale bars, 12.5 µm. H) Enumeration of HEY cells that were positive for both p-HH3 and active caspase-3 as shown in (G) and HEY cells that were treated with CTRL (DMSO), dasatinib alone (50 nM), or paclitaxel alone (3 nM). Five hundred cells were counted. *P = .021 vs paclitaxel alone. All P values were calculated using the two-sided Student t test.
Role of p27
Kip1 in Dasatinib-Induced Enhancement of Paclitaxel Activity Dasatinib causes human ovarian cancer cells to arrest at the G 1 phase of the cell cycle in (14) . Because increased levels of the p27 Kip1 protein also cause cells to arrest in the G 1 phase of the cell cycle (25), we examined the effect of dasatinib on p27
Kip1 expression. Immunoblot analysis of HEY cells revealed that dasatinib induced p27
Kip1 protein expression in a time-dependent manner (Figure 4, A) . Kip1 knockdown on dasatinib-induced G 1 arrest. HEY cells were transfected with a p27
Kip1 siRNA or a control siRNA 48 hours before treatment with dasatinib (50 nM), paclitaxel (3 nM), both agents combined (Das + Pac), or DMSO (CTRL) for an additional 24 hours, then stained with PI, and subjected to cell cycle analysis by flow cytometry to quantify the percentage of cells in the G 1 phase of the cell cycle. *P = .026, **P = .
(two-sided Student t test). D) Effect of p27
Kip1 knockdown on combination treatment-induced apoptosis. HEY cells were transiently transfected with a p27
Kip1 siRNA or a control siRNA for 48 hours and then treated for 24 hours with dasatinib (50 nM), paclitaxel (3 nM), both agents combined, or DMSO (CTRL). The sub-G 1 fraction, assessed by flow cytometry, was used to quantify apoptotic cells. *P = .012 (two-sided Student t test). Data shown in panels (D) and (E) are mean values from three independent experiments. E) Dose-dependent induction of p27
Kip1 expression in the absence of doxycycline in HEY cells infected with a Tet-off p27 adenovirus construct. HEY cells were infected with p27 adenovirus (Adp27) at the indicated multiplicities of infection (MOIs) and incubated for 24 hours in the absence or presence of 1 µg/mL doxycycline (DOX). p27
Kip1 expression was assessed by immunoblotting. F) Effect of exogenous p27
Kip1 expression on paclitaxelinduced apoptosis. HEY cells were infected in triplicate with the Tet-off p27 Kip1 adenovirus at an MOI of 10, incubated for 8 hours in the presence or absence of doxycycline, and then treated with paclitaxel (3 nM) for additional 24 hours. The sub-G 1 fraction, assessed by flow cytometry, was used to quantify apoptotic cells. *P = .036 (two-sided Student t test). Data shown were pooled from two independent experiments. Error bars represent 95% confidence intervals.
To examine whether dasatinib-induced p27
Kip1 protein expression was critical for dasatinib-mediated cell cycle arrest, we studied the effect of dasatinib on BrdU incorporation to measure the fraction of cells entering S phase in the absence and presence of p27 Kip1 siRNAs. Dasatinib treatment markedly decreased the percentage of HEY cells that incorporated BrdU compared with DMSO control (control vs dasatinib: 48% vs 16%, difference = 32%, 95% CI = 29% to 35%, P < .001) (Figure 4, B) . The siRNA-mediated knockdown of p27
Kip1 partially blocked the dasatinib-mediated inhibition of BrdU incorporation compared with control siRNA (control siR + dasatinib vs p27
Kip1 siR + dasatinib: 16% vs 31%, difference = 15%, 95% CI = 13% to 17%, P = .018) (Figure 4, B) .
As expected, dasatinib treatment increased the percentage of HEY cells at G 1 phase compared with DMSO (63% vs 48%, difference = 15%, 95% CI = 13.5% to 16.5%, P = .026) (Figure 4, C) .
Knockdown of p27
Kip1 expression with the p27 Kip1 siRNA 1 almost completely blocked dasatinib-induced increase in the percentage of HEY cells at G 1 phase (Figure 4, C) . Another p27 Kip1 siRNA showed a similar effect (data not shown). Both p27
Kip1 siRNAs were effective in decreasing p27
Kip1 protein expression (Supplementary Figure 4 , available online). These findings indicate that dasatinibinduced p27
Kip1 expression appears to be important for dasatinibmediated inhibition of BrdU incorporation and G 1 arrest.
We next examined the effect of p27 Kip1 expression on apoptosis induced by treatment of HEY cells with dasatinib plus paclitaxel.
HEY cells transfected with a p27
Kip1 siRNA and treated with dasatinib plus paclitaxel had fewer apoptotic cells compared with similarly treated cells transfected with a control siRNA (percentage of cells in sub-G 1 fraction, control siRNA vs p27
Kip1 siRNA: 42.5% vs 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017) (Figure 4, D) . These observations suggest that dasatinib-induced p27
Kip1 is critical for dasatinib-enhanced paclitaxel cytotoxicity in ovarian cancer cells.
To further validate these observations and to test the effect of exogenous expression of p27
Kip1 on paclitaxel-induced cytotoxicity in the absence of dasatinib, we infected HEY cells with an adenovirus construct that expresses a doxycycline-regulated form of human p27
Kip1 (19) . Expression of p27 Kip1 protein in infected cells was induced only in the absence of doxycycline (Figure 4 
, E). HEY cells infected with the p27
Kip1 adenovirus and incubated in absence of doxycycline (ie, exogenous p27
Kip1 expressed) had statistically significantly more paclitaxel-induced apoptosis compared with cells infected with the p27
Kip1 adenovirus and incubated in the presence of doxycycline (ie, exogenous p27
Kip1 not expressed) (20.6% vs 11.1%, difference = 9.5%, 95% CI = 8.1% to 10.9%, P = .036) (Figure 4, F) . Thus, increased expression of exogenous p27
Kip1 can enhance paclitaxel cytotoxicity in ovarian cancer cells.
The data presented in Figure 4 demonstrate that increased p27
Kip1 expression either by dasatinib or by exogenous expression is critical to enhance paclitaxel activity in human ovarian cancer cells.
Effect of Dasatinib-Induced p27
Kip1 on Paclitaxel Activity and Bcl-2 Expression in Human Ovarian Cancer Cells We next examined the mechanism by which induction of p27 Kip1 by dasatinib enhances paclitaxel-induced apoptosis in ovarian cancer cells by using an apoptosis PCR array to analyze expression levels of 84 genes involved in the apoptotic pathway in HEY cells treated for 24 hours with dasatinib (50 nM), paclitaxel (3 nM), dasatinib plus paclitaxel, or diluent (DMSO). Decreased expression of Bcl-2 mRNA and protein was produced by dasatinib alone and in combination with paclitaxel in multiple ovarian cancer cell lines and in xenografts (Figure 5, A; Supplementary Figure 5 , A-D, available online). We reasoned that if Bcl-2 inhibition was one of the mechanisms by which dasatinib enhanced paclitaxel cytotoxicity in ovarian cancer cells, Bcl-2 overexpression should attenuate dasatinib-enhanced paclitaxel cytotoxicity. Indeed, we observed that two HEY clones that stably overexpress Bcl-2 (Supplementary Figure 5 , E, available online) displayed decreased dasatinib-enhanced paclitaxel cytotoxicity compared with HEY clone that expresses empty vector pcDNA3 ( Figure 5, B) , suggesting that Bcl-2 inhibition plays a role in dasatinib-enhanced paclitaxel cytotoxicity.
We then asked whether dasatinib-induced p27 Kip1 expression affected dasatinib-induced Bcl-2 inhibition in ovarian cancer cells. To address this question, we examined the effect of siRNA-mediated knockdown of p27
Kip1 on Bcl-2 expression and caspase-3 activation in HEY cells treated with dasatinib, paclitaxel, or both agents in combination. Immunoblot analysis revealed that knockdown with the p27
Kip1 siRNA resulted in decreased caspase-3 activation (further supporting role of p27
Kip1 in combination treatment-induced apoptosis) and increased Bcl-2 protein expression compared with control siRNA-transfected cells treated with the combination (Figure 5, C) . qRT-PCR analysis also illustrated that compared with a control siRNA, siRNA-mediated knockdown of p27
Kip1 increased Bcl-2 mRNA expression ( Figure 5, D) , indicating that p27
Kip1 may negatively regulate Bcl-2 expression at the transcriptional level ( Figure 5, D) .
BCL2 gene transcription is regulated by the cAMP response element binding (CREB) family of transcription factors (26) , and phosphorylation of CREB transcription factors at serine 133 is associated with its transcriptional activity (27) . Therefore, we examined the effect of p27
Kip1 expression on phosphorylation of CREB at serine 133 in HEY cells transfected with a control siRNA or p27
Kip1 siRNA and treated with diluent (control), dasatinib, paclitaxel, or both agents in combination. Compared with control siRNA-transfected cells, siRNA-mediated knockdown of p27 Kip1 increased CREB phosphorylation and Bcl-2 expression in diluent-treated control cells ( Figure 5, C) . Thus, the data shown in Figure 5 , B-D suggest that dasatinib-induced p27
Kip1 enhances paclitaxel-induced apoptosis by negatively regulating Bcl-2 expression in human ovarian cancer cells.
Kip1 on Cdk1 Expression in Ovarian Cancer Cells A previous study of hepatocytes indicated that during M phase of the cell cycle, p27
Kip1 degradation is required for activation of Cdk1, a key regulator of entry into M phase (28) . In addition, overexpression of p27
Kip1 expression has been shown to enhance paclitaxelinduced apoptosis in cells with a defective retinoblastoma gene (29) . These reports suggest that both p27
Kip1 and Cdk1 may regulate paclitaxel sensitivity. To study the possible link between p27 Kip1 and Cdk1, we first examined the effect of dasatinib and paclitaxel on expression and phosphorylation of Cdk1. HEY cells or mice bearing HEY xenograft tumors were treated with diluent (control), dasatinib, paclitaxel, or both agents in combination as described in "Materials and Methods." Cell or tumor lysates were prepared and subjected to immunoblot analysis. Combined treatment of HEY cells or mice bearing HEY xenograft tumors with dasatinib and paclitaxel markedly inhibited Cdk1 expression and phosphorylation compared with treatment with dasatinib or paclitaxel alone in vitro and in vivo ( Figure 6, A and B, Supplementary Figure 6 , A, available online). However, siRNA-mediated knockdown of p27 Kip1 protein diminished the ability of the combination treatment to inhibit expression of phospho-Cdk1 or total Cdk1 (Figure 6, B) . Dasatinib alone also decreased expression and phosphorylation of (HEY-pcDNA3) , or a Bcl-2 expression plasmid (two independent clones, HEY-BCL2 19 and HEYBCL2 27) treated as described in (A). The sub-G 1 fraction, assessed by flow cytometry, was used to quantify apoptotic cells.
*P = .043, **P = .035 (two-sided Student t test). C) Effect of p27
Kip1 knockdown on Bcl-2 protein expression and apoptosis. HEY cells were transiently transfected with a p27
Kip1 silencing RNA (siRNA) or a control siRNA for 48 hours, then treated with dasatinib (50 nM), paclitaxel (3 nM), the combination (D + P), or DMSO (C) for 24 hours. Total protein was prepared and analyzed by immunoblotting for p27 Kip1 , Bcl-2, active caspase-3, and serine 133-phosphorylated cAMP response element binding (p-Ser133 CREB). GAPDH was used as the loading control. D) Effect of p27
Kip1 knockdown on Bcl-2 mRNA expression. HEY cells were treated as described in (C), and total RNA was prepared for real-time reverse transcription-polymerase chain reaction analysis of Bcl-2 mRNA expression. *P = .023 (two-sided Student t test). Data shown in panels (B) and (D) were pooled from three independent experiments; error bars correspond to 95% confidence intervals.
Cdk1 but to a lesser extent compared with the combination treatment (Figure 6, A) . These data suggest that dasatinib-induced p27
Kip1 may regulate Cdk1 expression. Given that Cdk1 was previously reported to coimmunoprecipitate with p27
Kip1 in hepatocytes (28), we next conducted experiments to examine whether Cdk1 and p27
Kip1 coimmunoprecipitate in ovarian cancer HEY cells. Both p27
Kip1 and Cdk1 were mutually detected in the respective complexes immunoprecipitated with Cdk1 or p27
Kip1 antibody (Figure 6 , C). We also tested the potential interaction of p21 Cip1 (another important Cdk inhibitor in the G 1 and M phases of the cell cycle) with Cdk1 and found that these proteins coimmunoprecipitated, but to a much lesser extent than p27 Kip1 and Cdk1, suggesting that p21 Cip1 has a less important role than p27
Kip1 with regard to the effects of dasatinib treatment (data not shown). We next examined whether treatment of the cells with dasatinib, paclitaxel, or the combination affected coimmunoprecipitation of p27 Kip1 and Cdk1. In cells treated with dasatinib, a considerable amount of p27 Kip1 protein coimmunoprecipitated with Cdk1, even though the level of Cdk1 in crude lysates of dasatinibtreated cells was reduced compared with that in lysates of DMSOtreated cells (Figure 6, D) . By contrast, only a trace of p27 Kip1 coimmunoprecipitated with Cdk1 in lysates of diluent-treated control cells (Figure 6, D) . Importantly, a considerable amount of p27
Kip1 protein coimmunoprecipitated with Cdk1 in the cells treated with dasatinib and paclitaxel, despite a noticeable reduction in the level of Cdk1 protein in the lysates (Figure 6, D) . These data suggest that dasatinib-induced p27 Kip1 interacts (directly or indirectly) with Cdk1 and inhibits its phosphorylation and expression in human ovarian cancer cells.
To define the role of Cdk1 inhibition in enhancing paclitaxel cytotoxicity of HEY ovarian cancer cells, we used several approaches. First, HEY cells were treated with paclitaxel or diluent in the presence or absence of BML-259, a selective inhibitor of Cdk1, and subjected to flow cytometric analysis to determine the Kip1 on paclitaxel activity and Cdk1 expression. A) Immunoblot analysis of phosphorylated (active) Cdk1 and total Cdk1. Total protein from HEY cells treated for 24 hours with 50 nM dasatinib (Das), 3 nM paclitaxel (Pac), the combination (D + P), or dimethyl sulfoxide (DMSO; C) was analyzed for phosphorylated (p-T160-CDK1) and total Cdk1 and p27
Kip1 expression by immunoblotting. The control for equal protein loading was glyceraldehyde 3-phosphate dehydrogenase (GAPDH). B) Effect of p27
Kip1 knockdown on active and total Cdk1 levels in HEY cells treated with dasatinib, paclitaxel, the combination, or DMSO. HEY cells were transfected with p27
Kip1 silencing RNA (siRNA) or control siRNA for 48 hours, then treated for 24 hours as in (A). Total protein was analyzed for active and total Cdk1 by immunoblotting. C) Coimmunoprecipitation (IP) experiment. Whole-cell lysates of HEY cells were equally divided into three parts and incubated (IP) with a murine anti-p27Kip1 antibody, a mouse antiCdk1 antibody, or mouse serum as control (CTRL). The immunoprecipitated complexes were analyzed by immunoblotting (WB) with a rabbit anti-Cdk1 antibody or a rabbit anti-p27
Kip1 antibody. D) Effect of dasatinib and paclitaxel treatment on coimmunoprecipitation of p27 Kip1 and Cdk1. Whole-cell lysates prepared from HEY cells treated as described in (A) were immunoprecipitated with a mouse Cdk1 antibody. The lysates and immunoprecipitated complexes were analyzed by sequential immunoblotting with antibodies against Cdk1, p27 Kip1 , and GAPDH. E) Effect of siRNA knockdown of Cdk1 on paclitaxel-induced apoptosis. HEY cells were transiently transfected with two Cdk1 siRNAs or a control siRNA for 48 hours and then treated for 24 hours with paclitaxel (3 nM) or DMSO (CTRL). The sub-G 1 fraction, assessed by flow cytometry, was used to quantify apoptotic cells. *P < .001 vs control siRNA plus paclitaxel (two-sided Student t test). F) Overexpression of Cdk1. HEY cells were transiently transfected with the pCMV-Cdk1 expression plasmid (pCdk1) or empty vector (pCMV). Total protein was prepared 48 hours after transfection and analyzed for Cdk1 expression by immunoblotting. G) Effect of Cdk1 overexpression on paclitaxel-induced apoptosis. HEY cells were transiently transfected with the pCdk1 expression plasmid or empty vector (pCMV) for 48 hours and then treated with paclitaxel (3 nM) for another 24 hours. The sub-G 1 fraction, assessed by flow cytometry, was used to quantify apoptotic cells. *P = .038 (two-sided Student t test). Data shown in panels (E) and (G) were pooled from three independent experiments; error bars correspond to 95% confidence intervals. CI = 16.4% to 20.6%, P < .001; Cdk1 siRNA 13 plus paclitaxel vs control siRNA plus paclitaxel: 35.4% vs 22.1%, difference = 13.3%, 95% CI = 12.8% to 13.8 %, P < .001) (Figure 6, E) . Third, HEY cells that were transiently transfected with a Cdk1 expression plasmid (Figure 6 , F) and treated with paclitaxel had a smaller sub-G 1 fraction compared with cells transiently transfected with empty vector and treated with paclitaxel (Cdk1 + paclitaxel vs pCMV + paclitaxel: 22.1% vs 27.2%, difference = 5.1%, 95% CI = 4.8% to 5.4%, P = .038) (Figure 6, G) . Thus, Cdk1 expression inversely affects paclitaxel-induced apoptosis in ovarian cancer cells and that inhibition of Cdk1 can enhance paclitaxel-induced apoptosis.
Modulation of Paclitaxel-Induced M Phase Arrest by p27
Kip1 in Ovarian Cancer Cells
To further investigate the role of p27
Kip1 expression in paclitaxel activity in ovarian cancer cells, HEY cells were transiently transfected with a p27
Kip1 siRNA or a control siRNA, synchronized at the G 1 -S transition with a single thymidine block, and then transferred to thymidine-free medium containing paclitaxel. Immunoblot analysis of cell lysates prepared at various times after release from the thymidine block was performed to examine the effects of p27
Kip1 expression on paclitaxel-induced mitotic arrest and apoptosis. Cells transfected with the control siRNA (ie, cells that expressed p27
Kip1 protein) entered M phase at 4 hours (as indicated by an increase in phosphorylated histone H3 expression), peaked in M phase at 8 hours, and then gradually exited M phase (Figure 7, A) . By 14 hours after release in the presence of paclitaxel, there was a marked reduction in phosphorylated histone H3 expression, indicating rapid reduction in M phase cells, consistent with the notion that cells that expressed p27
Kip1 underwent an active exit from paclitaxel-induced mitotic arrest. By contrast, in the presence of paclitaxel, cells transfected with the p27
Kip1 siRNA (ie, cells that lacked p27
Kip1 expression) peaked in M phase at 12 hours after released from thymidine block and remained in M phase. By 16 hours after release in the presence of paclitaxel, a substantial amount of phosphorylated histone H3 expression remained (indicating cells in M phase) demonstrating that paclitaxel-induced M phase arrest persisted in the absence of p27 Kip1 (Figure 7 , B). These data suggest that cells that did not express p27Kip1 had a delayed exit from paclitaxel-induced mitotic arrest. In the presence and absence of p27 Kip1 expression (Figure 7, A) , further supporting our previous observations (Figures 4 and 6 ). These data suggest that p27
Kip1 can modulate paclitaxel-induced M phase arrest and apoptosis by promoting mitotic slippage in ovarian cancer cells.
Effect of Dasatinib on Tyrosine, Serine, and Threonine Phosphorylation and Half-life of p27
Kip1 in Human Ovarian Cancer Cells The data presented above ( Figures 5 and 6 ) suggest that dasatinib increases the expression of p27
Kip1 and enhances paclitaxel cytotoxicity in human ovarian cancer cells by inhibiting expression of the antiapoptotic protein Bcl-2 and by decreasing expression of Cdk1.
How dasatinib increases p27
Kip1 protein expression in ovarian cancer cells is still not known. The p27
Kip1 protein level is primarily regulated post-transcriptionally at the levels of both protein translation and protein stability, and ubiquitin-and proteasome-mediated proteolysis is the major post-transcriptional pathway for regulation of p27
Kip1 protein (25) . A number of serine and threonine kinases have been identified to directly phosphorylate p27
Kip1 protein and control its expression and subcellular localization. Phosphorylation of p27
Kip1 protein on Thr187 by Cdk2 prepares p27 Kip1 protein for binding to ubiquitin ligase SCF
Skp2
, which leads to 26S proteasome degradation (30) . AKT phosphorylates p27
Kip1 at Thr157, which causes p27
Kip1 to exit the nucleus (31) (32) (33) . Serine 10 phosphorylation of p27
Kip1 by the mitogen-induced kinase hKIS increases p27
Kip1 proteolysis (34) . Of greater relevance to this study, tyrosine phosphorylation of p27 Kip1 protein at the 74/88/89 sites by the SF and Abl kinases, the targets of dasatinib, modulates its inhibitory activity by Kip1 siRNA (B), synchronized at G 1 -S by thymidine block, released from thymidine block, and treated with 3 nM paclitaxel (Pac). Whole-cell lysates were prepared at increasing times of paclitaxel exposure and subjected to immunoblot analysis of the M phase marker phosphorylated histone H3 (p-HH3), Cdk1, active caspase-3, and p27
Kip1 . Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control for equal protein loading. Expression of p-HH3, Cdk1, and active caspase-3 were digitized, normalized to GAPDH expression, and expressed as fold change compared with the respective levels at the 0-hour time point, which were set to 1.
converting p27
Kip1 from a bound inhibitor to a bound non-inhibitor of p27
Kip1 -Cdk4/6-cyclin D complexes and destabilize p27
Kip1 protein by promoting subsequent threonine 187 phosphorylation (35, 36) .
To study the effects of dasatinib on p27 Kip1 expression, localization, and p27
Kip1
-phosphorylating kinases, HEY cells treated with either dasatinib or DMSO control were fractionated into cytoplasm and nuclei, and lysates of each fraction were subjected to immunoblot analysis with various p27 Kip1 -related antibodies. We found that compared with DMSO, dasatinib treatment increased p27
Kip1 expression in the nucleus and suppressed Src phosphorylation at tyrosine 416 (Figure 8, A) . Cytoplasmic levels of p27
Kip1 in dasatinib-treated cells were also moderately increased compared with that in DMSO-treated cells (Figure 8, A) . Dasatinib treatment also markedly inhibited Cdk2 and AKT phosphorylation (Figure 8,  A) . As expected, dasatinib-induced p27
Kip1 coimmunoprecipitated with Cdk2 and, to a lesser extent, with Cdk4 (Figure 8, B) . Treatment of HEY cells with dasatinib, an inhibitor of Src family and Abl kinases (Figures 2, A, B and 8, A) , reduced tyrosine phosphorylation of p27 Kip1 (Figure 8, C) . Dasatinib treatment also suppressed phosphorylation of p27
Kip1 protein at Thr187, Ser10, and Thr157 (Figure 8, D) , all of which have been reported to control the stability of this protein (37) .
To measure the half-life of dasatinib-induced p27 Kip1 , HEY cells were treated with dasatinib or DMSO (diluent control) for 24 hours followed by treatment with cycloheximide, an inhibitor of protein synthesis. Immunoblot analysis revealed that the level of p27
Kip1 protein in dasatinib-treated cells declined gradually with increasing time of cycloheximide treatment and at a much slower rate than that in DMSO-treated cells (Figure 8, E) . After normalization of p27
Kip1 expression with the loading control (GAPDH), the half-life of p27
Kip1 in dasatinib-treated cells was 6.0 hours, whereas the half-life of p27
Kip1 in DMSO-treated cells was 2.5 hours (Figure 8, F) . Taken together, these data show that dasatinib increases the amount of nuclear p27
Kip1 by inhibiting tyrosine, serine, and threonine phosphorylation of p27
Kip1 and prolonging its half-life in human ovarian cancer cells. Kip1 , Cdk2, and AKT expression. HEY cells were treated for 24 hours with 50 nM dasatinib (Das) or dimethyl sulfoxide (DMSO) and subjected to subcellular fractionation into cytoplasm and nuclei. Cytoplasmic (CE) and nuclear (NE) extracts were analyzed by immunoblotting for total and tyrosine 416-phosphylated Src (p-Y416 Src), p27
Kip1 , Cdk1, and serine 473-phosphorylated AKT (p-S473-AKT). Nuclear poly (ADP-ribose) polymerase (PARP) and cytoplasmic a-tubulin were used to control for efficient subcellular fractionation. B) Coimmunoprecipitation experiment. Crude lysates were prepared from HEY cells treated as described in (A) and used for immunoprecipitation (IP) with a mouse p27
Kip1 antibody. Immunoprecipitated complexes were analyzed by immunoblotting (WB) with antibodies against Cdk2 and CDdk4. IgG HC = immunoglobin heavy chain. C) Effect of dasatinib on tyrosine phosphorylation of p27 Kip1 . HEY cells were treated and subjected to immunoprecipitation as described in (B). The immunoprecipitates were subjected to immunoblotting with a phospho-tyrosine antibody (p-Tyr) to detect p27
Kip1 tyrosine phosphorylation (p-Tyr p27 Kip1 ) and a p27 Kip1 antibody (p27). IgG LC = immunoglobin light chain. D) Effect of dasatinib on serine and threonine phosphorylation of p27Kip1. HEY cells were treated as described in (A). Immunoblotting was performed with three specific antibodies to detect phosphorylation at threonine 187, serine 10, and threonine 157 of p27 Kip1 . E) Effect of dasatinib on the half-life of p27 Kip1 protein. HEY cells were treated for 24 hours with 50 nM dasatinib or DMSO, washed, and treated with 5 µg/mL of cycloheximide (CHX) for the indicated times. The cells were harvested and use to prepared whole-cell lysates, which were subjected to immunoblot analysis with antibodies against p27 Kip1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The immunoblot shown was a representative of results obtained in three independent experiments. F) Quantitation of p27
Kip1 expression. The p27 Kip1 bands on immunoblots from three experiments including the one shown in (E) were digitized, normalized to the levels of GAPDH, and expressed as mean levels (error bars correspond to 95% confidence intervals). The p27 Kip1 expression at 0 hour for both dasatinib-and DMSO-treated groups was set at 1.
Discussion
Through a kinome siRNA library screen and subsequent validation of hits with multiple siRNAs, we identified Src family and Abl kinases as modulators of paclitaxel sensitivity in human ovarian cancer cells. We showed that dasatinib, as an inhibitor of Src family and Abl kinases, enhances paclitaxel activity in vitro and in vivo. Dasatinib enhanced paclitaxel cytotoxicity predominantly by enhancing apoptosis and to a lesser degree by inducing mitotic catastrophe. Treatment of human ovarian cancer cells with dasatinib induced p27
Kip1 protein expression and played a critical role in the enhancement of paclitaxel-induced apoptosis through suppressing Bcl-2 and inhibiting Cdk1 at M phase. Dasatinib increased the half-life of nuclear p27
Kip1 protein by reducing its phosphorylation.
Inhibition of Src kinase has been reported to enhance the sensitivity of ovarian cancer cells to paclitaxel (38, 39) or docetaxel (40) . Our data establish that dasatinib enhances the cytotoxicity of paclitaxel in vitro and in vivo. More importantly, our data reveal underlying mechanisms-induction of apoptosis and mitotic catastrophe-by which dasatinib enhances paclitaxel activity and identify several key molecules, including p27 Kip1 , Bcl-2, and Cdk1, that are involved in this interaction.
We identified p27 Kip1 as a critical molecule that mediates dasatinib-induced enhancement of sensitivity to paclitaxel.
Knockdown of p27
Kip1 expression with siRNAs diminished the ability of dasatinib to enhance paclitaxel-induced apoptosis as measured by the sub-G 1 fraction of cells on flow cytometry and by caspase-3 activation. In addition, forced expression of p27 Kip1 increased the sensitivity of ovarian cancer cells to paclitaxel. Our finding, that p27
Kip1 has a critical role in mediating the effect of dasatinib in combination with paclitaxel, is also consistent with a number of studies in the literature. For example, UCN-01, an inhibitor of G 1 phase and MAP kinase, induces p27
Kip1 expression and G 1 arrest in HL60 and Jurkat cells and enhances paclitaxelinduced cell death (41) . Resveratrol (3,4′,5-trihydroxystilbene), a natural antioxidant in red wine, was found to induce p27 Kip1 expression and enhance induction of apoptosis by paclitaxel in lung cancer cells (42) . Lapatinib, a dual inhibitor of epidermal growth factor receptor and HER2 tyrosine kinases, was found to induce p27
Kip1 expression and G 1 arrest and potentiate paclitaxeland cisplatin-mediated cell death in gastric cancer cells (43) . Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, was found to cause G 1 and G 2 arrest, induce expression of p27 Kip1 , and enhance paclitaxel activity in ovarian cancer cells (44) . Trastuzumab, a humanized antibody against HER2, exerts antitumor effects through induction of p27
Kip1 expression and G 1 arrest in HER2-overexpressing breast cancer cells (19) and has been shown to enhance the effectiveness of paclitaxel chemotherapy in patients whose tumors overexpress HER2 (45) . Finally, overexpression of exogenous p27
Kip1 has been shown to potentiate paclitaxel-induced apoptosis in SaOs-2 cells (29) .
However, several reports show that an increase in p27 Kip1 expression and G 1 arrest can diminish paclitaxel activity (46, 47) . Several factors could contribute to this apparent discrepancy. First, differing signaling abnormalities in different cancer cell lines, differing concentrations of paclitaxel, or differing lengths of treatment might alter the effects of p27
Kip1 and cell cycle arrest on paclitaxelinduced apoptosis (47) . Second, paclitaxel can exert anticancer effects via mechanisms that do not involve M phase, such as Bcl-2 hyperphosphorylation, c-Raf-1 phosphorylation, and angiogenesis, which may be observed in some cancer cell lines but not in others (47) . Drugs that induce p27
Kip1 expression and that work synergistically with the non-M phase mechanisms of paclitaxel could enhance paclitaxel activity. Third, p21 Cip1 -induced G 1 arrest but not p27 Kip1 -induced G 1 arrest was found to interfere with paclitaxel activity in colon cancer cells (48) . The ability of dasatinib to induce G 1 arrest through p27
Kip1 rather than p21 Cip1 in human ovarian cancer cells (Figure 6 ) might produce enhancement rather than inhibition of paclitaxel activity.
Our study has further revealed two new mechanisms by which dasatinib-induced p27
Kip1 enhances paclitaxel-induced apoptosis: decreased expression of the antiapoptotic protein Bcl-2 and increased Cdk1-regulated mitotic slippage. Both mRNA and protein levels of Bcl-2 were reduced by p27
Kip1 expression in ovarian cancer cells. Given the fact that p27
Kip1 is not a transcription factor and thus unlikely to interact directly with the Bcl-2 promoter region, the effects of p27
Kip1 expression on Bcl-2 mRNA level are likely to be indirect. Indeed, we found that dasatinib inhibits the phosphorylation of CREB transcription factor, an upstream regulator of the BCL2 gene (26) , and decreases the activity of BCL2. In addition, p27
Kip1 may exert its effects on Bcl-2 expression by regulating other transcriptional factors, such as E2F, FOXO, NF-kB, or AP2, which are all known to bind directly to the Bcl-2 promoter (49,50). We found that stable overexpression of Bcl-2 in ovarian cancer cells partially blocked dasatinib-enhanced paclitaxel activity, further suggesting that p27
Kip1 -mediated Bcl-2 suppression played a role in dasatinibenhanced paclitaxel cytotoxicity.
The primary role of p27 Kip1 in normal cells has been thought to center on inhibition of Cdk2 expression and induction of G 1 arrest (37, 51) . To our knowledge, the function of p27
Kip1 in M phase has not been addressed. Entry into and progression through mitosis are regulated by activation of Cdk1-cyclin B complexes via phosphorylation of Cdk1 (51, 52) . SKP2-regulated p27
Kip1 has been reported to interact with Cdk1 and play a role in mitosis in hepatocytes (28) . In this report, we have demonstrated that dasatinib-induced p27
Kip1 coimmunoprecipitated with Cdk1 and inhibited Cdk1, which contributed to dasatinib-enhanced paclitaxel activity. Compared with p27 Kip1 knockdown, p27
Kip1 expression promoted mitotic exit in cells treated with paclitaxel, which may result in mitotic slippage (ie, the exit from mitosis without division) (53) . Given our observation of an increase in multinucleated cells after treatment with dasatinib and paclitaxel and the fact that mitotic slippage can occur when Cdk1-cyclin B activity is inhibited (54), we suggest that dasatinib-induced p27
Kip1 expression may facilitate mitotic slippage and allow paclitaxel-treated cells to enter interphase without undergoing chromosome separation or cytokinesis. Mitotic slippage is well known to induce a multinucleated phenotype (54, 55) and postmitotic cell death (54, 56, 57) . Moreover, flavopiridol enhancement of paclitaxel-induced apoptosis in the setting of combination treatment paclitaxel and flavopiridol was also associated with an accelerated exit of cells from mitosis (47) . Therefore, it is reasonable to speculate that both inhibition of apoptosis (through decreased Bcl-2 expression) and promotion of mitotic slippage (through inhibition of Cdk1 expression) by dasatinib contribute to increased apoptosis and mitotic catastrophe with the combined treatment with dasatinib and paclitaxel that we observed in this study. However, the detailed mechanism by which p27
Kip1 increases mitotic slippage remains to be determined.
Although the primary role of dasatinib to date has been in the management of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant to imatinib (22, 58) , dasatinib has been shown to exhibit impressive activity against a number of solid tumors. For example, dasatinib was found to inhibit the growth of breast cancer cell lines that do not express the estrogen receptor, progesterone receptor, or HER2, as well as the growth of a subset of lung cancer and ovarian cancer cell lines (59) (60) (61) . Evidence presented in this study supports clinical testing of dasatinib in combination with paclitaxel for patients with ovarian cancer. As an FDAapproved drug, dasatinib could be readily tested in combination with paclitaxel in clinical trials. Clinical use of dasatinib in combination with paclitaxel is also supported by a recent report that dasatinib inhibited the growth of 24 (70%) of 34 human ovarian cancer cell lines tested and enhanced the anticancer effects of both paclitaxel and carboplatin (61) .
Identification of biomarkers that can predict clinical efficacy of dasatinib and paclitaxel combination therapy in cancers would be ideal for future clinical testing. A number of preclinical studies have already reported some potential biomarkers that predict dasatinib effectiveness. For example, expression of moesin, caveolin-1, and yes-associated protein-1 have been found to predict response to dasatinib in triple-negative breast cancer (59, 60) . Urokinase-type plasminogen activator and EphA2 expression were identified as sensitive biomarkers that could predict dasatinib response in prostate cancer (62) . Phosphorylation of Src Tyr416 and paxillin Tyr118 appear to be biomarkers for response to dasatinib in colon cancer (63) . This study identified three key molecules-p27 Kip1 , Bcl-2, and Cdk1-involved in dasatinib and paclitaxel combination treatment that might serve as predictive biomarkers. Specifically, increased p27
Kip1 expression, decreased Bcl-2 expression, and decreased Cdk1 expression following treatment might predict response to the combination treatment with dasatinib and paclitaxel in human ovarian cancer. Biopsy of cancers before and shortly after the initiation of treatment would be required to determine these changes. Future studies of circulating tumor cells might facilitate such determinations without the need for invasive biopsies.
This study has several limitations. Src family and Abl kinases were identified as regulators of paclitaxel sensitivity in human ovarian cancer SKOv3 and HEY cells. Although we have validated this finding in additional ovarian cancer cell lines (ie, OVCA420 and ES2), validation in additional ovarian cancer xenograft models may better establish the importance of these particular kinases. Dasatinib inhibits a variety of tyrosine kinases in addition to those of the Src and Abl families, including c-Kit, PDGFR, and multiple Eph kinases (20, 21) . Consequently, some of the mechanisms of action identified for dasatinib in this study may represent off-target effects mediated through these other kinases. Specific inhibition of individual Src family or Abl kinases with individual siRNAs could be exploited to link these particular kinases to regulation of p27 Kip1 , Bcl2, and Cdk1. Results of this study have revealed that dasatinib induces p27 Kip1 expression in the nucleus by inhibiting its phosphorylation and prolonging its half-life. Further studies will be needed to understand how inhibition of the Src family and Abl kinases regulates the kinases (such as AKT, Cdk2) that phosphorylate p27
Kip1 in the nucleus. Our results indicate that dasatinib enhances paclitaxel-associated apoptosis by increasing p27
Kip1 expression, suppressing Bcl-2 expression, inhibiting Cdk1 expression, and increasing mitotic slippage. Further studies will be required to understand how p27 Kip1 modulates expression of Bcl-2 and Cdk1 and to determine the mechanism by which p27
Kip1 increases mitotic slippage. Finally, clinical studies are needed to confirm whether p27
Kip1 increases in ovarian cancers from patients who receive dasatinib in combination with paclitaxel and whether such an increase predicts a subsequent response to therapy.
